The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
Yasushi Honda(National Institute for Environmental Studies), Atsushi Nakajima(Yokohama City University)
Cited by 169
Related Papers
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
|JAMA|2024|200
Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
|Scientific Reports|2017|128
Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
|Scientific Reports|2016|83